4SC AG RPE
What is the RPE of 4SC AG?
The RPE of 4SC AG is €53.619k
What is the definition of RPE?
Revenue per employee (RPE) is revenue divided by the number of employees of an organization.
= net income / number of employees
RPE of companies in the Health Care sector on XETRA compared to 4SC AG
What does 4SC AG do?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Companies with rpe similar to 4SC AG
- Jumia Technologies AG has RPE of $53.468k
- LSL Property Services Plc has RPE of £53.511k
- Neovasc has RPE of $53.549k
- Stanley Furniture has RPE of $53.560k
- VR Education Plc has RPE of €53.618k
- City of London plc has RPE of £53.618k
- 4SC AG has RPE of €53.619k
- Greenpro Capital has RPE of $53.672k
- Xinyang Maojian has RPE of HKD$53.752k
- I.Céram SA has RPE of €53.842k
- Génomic Vision SA has RPE of €53.852k
- Profound Medical has RPE of $53.973k
- Nikola has RPE of $54.018k